…and the Billion-Dollar Battle Over Addyi
By Jamie Bussin, featuring Cindy Eckert
When I interviewed Cindy Eckert, on Episode #428 of The Tonic Talk Show/Podcast, I was expecting to discuss the regulatory mechanics behind a controversial drug approval. What I uncovered instead was a decade-long case study in how culture, gender bias, and regulatory discretion can collide inside the U.S. Food and Drug Administration. This is a digest of that conversation.
At the centre of the story is Addyi, the first and only FDA-approved pill for hypoactive sexual desire disorder (HSDD) in premenopausal women. Approved in 2015, Addyi was designed to treat a condition characterized by persistent low sexual desire that causes personal distress. According to Eckert, the science supporting HSDD had existed for decades. The real fight, she says, was not about whether the condition was legitimate. It was about whether treating it mattered.
Understanding the FDA Approval Process
To appreciate the controversy, it helps to understand how the FDA evaluates new drugs.
The FDA approval process generally requires:
- Preclinical research – Laboratory and animal studies to assess safety.
- Clinical trials (Phase I–III) – Human testing to evaluate safety, dosing, and effectiveness.
- New Drug Application (NDA) submission – Comprehensive data provided to the FDA.
- Risk-benefit analysis – Regulators determine whether the therapeutic benefits outweigh the known risks.
Every drug approved in the United States must pass through this framework. Risk and benefit are always weighed against one another. No medication is risk-free. The question is whether the benefit justifies those risks.
Eckert’s argument is that in women’s sexual health, that equation was not being applied evenly.
The Comparison No One Could Ignore
In 1998, the FDA approved Viagra for erectile dysfunction. That drug was fast-tracked and approved within six months, reflecting what regulators determined to be a significant unmet medical need. By contrast, Addyi’s path to approval took six years.
At the time Eckert began her effort, there were more than two dozen FDA-approved treatments for male sexual dysfunction. For women, there were none. Yet HSDD had been recognized in medical literature since 1977. Brain imaging studies showed measurable differences in women experiencing the disorder compared to those who were not. Clinical endpoints were clearly defined. Standardized questionnaires and outcome measures were used in trials.
The science, Eckert maintains, was there.
What stalled progress, in her view, was how regulators perceived the benefit side of the equation.
“When something goes wrong for men, we say biology,” she told me. “When something goes wrong for women, we say emotion.”
That distinction, she argues, shaped how Addyi was evaluated.
Risk, Benefit, and Cultural Conditioning
The FDA does not operate in a vacuum. Regulators are scientists and physicians, but they are also human. Eckert believes cultural conditioning influenced how Addyi’s risks were weighed.
In any drug review, regulators examine side effects and safety concerns. Addyi’s profile included potential risks such as low blood pressure and fainting, particularly when combined with alcohol. These risks were scrutinized heavily.
But Eckert’s point is that scrutiny alone was not the issue. The question was whether the benefit, helping women regain sexual desire and improve intimate relationships, was valued as highly as similar benefits for men.
If the benefit is considered trivial, then even modest risks can appear unacceptable. If the benefit is considered meaningful, the same risks may be deemed reasonable.
According to Eckert, women’s sexual satisfaction was implicitly undervalued in that calculation.
The debate became public. Advocacy groups mobilized. Accusations of gender bias surfaced.
The approval marked a milestone, but not the end of the story.
A Billion-Dollar Sale and an Unfinished Mission
Shortly after approval, Eckert sold Sprout Pharmaceuticals in a deal reportedly valued at $1 billion. For many entrepreneurs, that would have been the closing chapter. …it wasn’t for her.
The acquiring company underwent restructuring and leadership changes. Addyi was not prioritized. The rollout stalled. For Eckert, who viewed the drug as part of a broader mission to change the conversation around women’s sexual health, that was unacceptable.
She later fought to reacquire and regain control of Addyi.
“This was never about a pill,” she told me. “It was about advancing a conversation.”
Her larger goal was ensuring that women had access to treatment options, and that the medical community treated sexual health as an integral part of overall health.
Has the Landscape Changed?
One of the most striking parts of our discussion was Eckert’s view that cultural momentum has shifted in recent years.
Conversations around menopause, perimenopause, and hormone replacement therapy have become more open. Younger physicians, she says, are less tolerant of dismissive attitudes toward women’s health concerns. Education has improved. Today, board-certified OB-GYNs and other specialists must demonstrate knowledge of HSDD and Addyi in their examinations.
That institutional shift may be as important as the drug itself.
If physicians are trained to recognize HSDD as a legitimate neurochemical condition,rather than simply stress, relationship dissatisfaction, or lifestyle issues, patients are more likely to receive evidence-based care.
The Broader Implications for Healthcare Equity
The documentary about Eckert’s battle, The Pink Pill, frames the story within a larger movement for healthcare equity and bodily autonomy. The Addyi saga forces a difficult question: On what basis do we decide which medical conditions deserve pharmaceutical treatment?
No one is required to take Addyi. But the controversy centered on whether women should have the option.
In the FDA approval process, objectivity is the goal. Data, endpoints, and statistical significance drive decisions. Yet Addyi’s journey suggests that societal assumptions can influence how that data is interpreted, particularly in areas tied to sexuality.
For decades, male sexual dysfunction was treated as a biological issue worthy of aggressive pharmaceutical innovation. Female sexual dysfunction was more often framed as psychological or relational.
Eckert’s challenge to the FDA was, at its core, a demand for equal valuation of women’s experiences.
A Case Study in Regulatory Reflection
Looking back, even some critics acknowledge that Addyi’s approval process sparked necessary conversations inside regulatory agencies. The debate highlighted how risk tolerance may vary depending on who stands to benefit.
The FDA’s mandate is to protect public health. But protecting health includes acknowledging that sexual health contributes to mental health, relationship stability, and overall well-being.
Addyi’s approval did not resolve every controversy. It did, however, force a recalibration of how female sexual health is viewed within the regulatory system.
From my perspective as an interviewer—and as someone who has dealt with regulatory systems in my former career as a commercial litigator, the Addyi story underscores a simple truth: systems are designed to be objective, but they are administered by people.
And people carry assumptions.
The FDA approval process remains one of the most rigorous in the world. Yet Addyi’s journey reminds us that scientific standards do not operate independently of culture.
Cindy Eckert’s fight was about more than one drug. It was about whether women’s sexual health would be recognized as medically significant. The answer, after years of resistance, was yes.
The bigger question now is whether that recognition will continue to shape how future therapies for women are evaluated, or whether each advance will require another battle.
